tradingkey.logo

Precigen Inc

PGEN
4.160USD
-0.030-0.72%
收盤 12/26, 16:00美東報價延遲15分鐘
1.47B總市值
虧損本益比TTM

Precigen Inc

4.160
-0.030-0.72%

關於 Precigen Inc 公司

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Precigen Inc簡介

公司代碼PGEN
公司名稱Precigen Inc
上市日期Aug 08, 2013
CEOSabzevari (Helen)
員工數量143
證券類型Ordinary Share
年結日Aug 08
公司地址20374 Seneca Meadows Parkway
城市GERMANTOWN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編20876
電話13015569900
網址https://precigen.com/
公司代碼PGEN
上市日期Aug 08, 2013
CEOSabzevari (Helen)

Precigen Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.32M
+20.22%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.15M
+12.00%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.14M
+11.34%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
595.77K
+26.11%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
579.24K
+27.13%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
346.07K
-33.50%
Ms. Nancy Howell Agee
Ms. Nancy Howell Agee
Independent Director
Independent Director
217.84K
+7.39%
Mr. Phil Tennant
Mr. Phil Tennant
Chief Commercial Officer
Chief Commercial Officer
65.03K
+10.16%
Mr. Cesar L. Alvarez
Mr. Cesar L. Alvarez
Independent Director
Independent Director
--
--
Mr. Donald P. Lehr
Mr. Donald P. Lehr
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.32M
+20.22%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.15M
+12.00%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.14M
+11.34%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
595.77K
+26.11%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
579.24K
+27.13%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
346.07K
-33.50%

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Service
781.00K
91.24%
Product
41.00K
4.79%
Other
34.00K
3.97%
由於公司未披露,未能獲取相關數據
業務
地區
業務USD
名稱
營收
佔比
Service
781.00K
91.24%
Product
41.00K
4.79%
Other
34.00K
3.97%

股東統計

更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Third Security, LLC
35.03%
Patient Capital Management, LLC
7.48%
Merck Serono SA
5.84%
William H. Miller III Living Trust
4.91%
Tang Capital Management, LLC
3.50%
其他
43.24%
持股股東
持股股東
佔比
Third Security, LLC
35.03%
Patient Capital Management, LLC
7.48%
Merck Serono SA
5.84%
William H. Miller III Living Trust
4.91%
Tang Capital Management, LLC
3.50%
其他
43.24%
股東類型
持股股東
佔比
Venture Capital
35.04%
Investment Advisor
15.87%
Individual Investor
7.79%
Hedge Fund
7.73%
Investment Advisor/Hedge Fund
6.52%
Corporation
5.84%
Research Firm
1.50%
Pension Fund
0.10%
Bank and Trust
0.05%
其他
19.56%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
286
222.21M
62.96%
+17.23M
2025Q2
298
229.52M
77.76%
-784.34K
2025Q1
334
228.75M
77.50%
-12.95M
2024Q4
336
223.34M
76.44%
-15.36M
2024Q3
342
222.44M
77.88%
+21.14M
2024Q2
350
183.56M
71.33%
-22.34M
2024Q1
356
187.95M
73.95%
-17.15M
2023Q4
369
187.18M
73.43%
-12.81M
2023Q3
377
185.65M
75.06%
-11.67M
2023Q2
383
181.15M
73.32%
-8.55M
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Third Security, LLC
128.72M
36.47%
+12.39M
+10.65%
Sep 17, 2025
Patient Capital Management, LLC
16.27M
4.61%
-1.10M
-6.35%
Jun 30, 2025
Merck Serono SA
20.65M
5.85%
--
--
Mar 31, 2025
William H. Miller III Living Trust
17.39M
4.93%
+17.39M
--
Jun 26, 2025
BlackRock Institutional Trust Company, N.A.
9.83M
2.79%
+271.44K
+2.84%
Jun 30, 2025
The Vanguard Group, Inc.
9.07M
2.57%
+274.07K
+3.12%
Jun 30, 2025
State Street Investment Management (US)
3.03M
0.86%
-9.03K
-0.30%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.75M
1.06%
+269.58K
+7.75%
Jun 30, 2025
Iridian Asset Management LLC
4.28M
1.21%
-307.15K
-6.70%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Inspire Small/Mid Cap ESG ETF
0.24%
ProShares Ultra Nasdaq Biotechnology
0.14%
iShares Micro-Cap ETF
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
State Street SPDR S&P Biotech ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
Direxion Daily S&P Biotech Bull 3X Shares
0.06%
iShares Biotechnology ETF
0.05%
iShares Russell 2000 Growth ETF
0.03%
ProShares UltraPro Russell2000
0.02%
查看更多
Inspire Small/Mid Cap ESG ETF
佔比0.24%
ProShares Ultra Nasdaq Biotechnology
佔比0.14%
iShares Micro-Cap ETF
佔比0.12%
Invesco Nasdaq Biotechnology ETF
佔比0.12%
State Street SPDR S&P Biotech ETF
佔比0.11%
Vanguard US Momentum Factor ETF
佔比0.1%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.06%
iShares Biotechnology ETF
佔比0.05%
iShares Russell 2000 Growth ETF
佔比0.03%
ProShares UltraPro Russell2000
佔比0.02%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Precigen Inc的前五大股東是誰?

Precigen Inc的前五大股東如下:
Third Security, LLC
持有股份:128.72M
佔總股份比例:36.47%。
Patient Capital Management, LLC
持有股份:16.27M
佔總股份比例:4.61%。
Merck Serono SA
持有股份:20.65M
佔總股份比例:5.85%。
William H. Miller III Living Trust
持有股份:17.39M
佔總股份比例:4.93%。
BlackRock Institutional Trust Company, N.A.
持有股份:9.83M
佔總股份比例:2.79%。

Precigen Inc的前三大股東類型是什麼?

Precigen Inc 的前三大股東類型分別是:
Third Security, LLC
Patient Capital Management, LLC
Merck Serono SA

有多少機構持有Precigen Inc(PGEN)的股份?

截至2025Q3,共有286家機構持有Precigen Inc的股份,合計持有的股份價值約為222.21M,占公司總股份的62.96% 。與2025Q2相比,機構持股有所增加,增幅為-14.79%。

哪個業務部門對Precigen Inc的收入貢獻最大?

在FY2025Q2,Service業務部門對Precigen Inc的收入貢獻最大,創收781.00K,占總收入的91.24% 。
KeyAI